Navigation Links
Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
Date:11/6/2013

LA JOLLA, Calif., Nov. 6, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended September 30, 2013 on Wednesday, November 13, 2013, after the U.S. financial markets close.

Regulus will host a conference call and webcast on Wednesday, November 13, 2013 at 5:00 pm Eastern Standard Time to discuss its third quarter 2013 financial results and recent company highlights. A live webcast of the call will be available online at www.regulusrx.com.  To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 93095033.  To access the telephone replay of the call, dial (855) 859-2056 (domestic) or (404) 537-3406 (international), passcode 93095033. The webcast and telephone replay will be archived on the company's website following the call. 

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company.   Regulus has a well-balanced microRNA therapeutic pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases.  Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122, for the treatment of chronic hepatitis C virus infection.  Regulus' commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi.  In addition, Regulus has formed a research collaboration with Biogen Idec around its emerging microRNA biomarkers platform. 

For more information, please visit http://www.regulusrx.com

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
2. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
3. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
4. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
5. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
6. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
7. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
8. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
9. Regulus to Present at Future Leaders in the Biotech Industry Conference
10. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
11. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... India , Jan. 24, 2017 Market Research Future has ... Market for Wound Closure Device is growing rapidly and expected to continue ... ... at a CAGR of 5% from 2013 to 2019 and reaching a ... of the forecasted period, 2016-2022 Global Wound Closure Device Market ...
(Date:1/24/2017)... Nev. , Jan. 24, 2017  The ... that specializes in high-value orthopaedic implants, announced the ... today. The OIC Tibial Nail ... tibia. Strategically placed proximal and distal screw holes ... hole that allows dynamization.  The nail is available ...
(Date:1/24/2017)... 2017 Trifecta Clinical , a leading ... Rick Ward to Vice President of Commercial ... also announcing the promotion of Ericka Atkinson ... Rick joins Trifecta from Greenphire where he was ... business development positions within the healthcare industry throughout his ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... to Thrive , Well-meaning studies such as the Fordham Institute’s High Stakes ... serve top students, such as including gifted or high-achieving students as a subgroup ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost water advocate ... Global Climate Change and Your Health on Voice America, once again welcomed one ...
(Date:1/24/2017)... ... ... A yellow fever outbreak in Brazil has infected over 100 people and claimed ... contact with infected mosquitos. The outbreak has sparked increased concern about the virus and ... multiple health organizations, the best way to prevent yellow fever is through vaccination. For ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... topics like finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. ... authors, Dr. Judith Coats and Dr. David Coats. In September of 1983, they ...
(Date:1/24/2017)... ... , ... “Mysteries Revealed On Speaking In Tongues”: an engaging and dynamic ... Christians. “Mysteries Revealed On Speaking In Tongues” is the creation of published author, Tina ... located in Michigan. , “We need to partner with Jesus and be the ...
Breaking Medicine News(10 mins):